Navigation Links
Therapix Biosciences to Present at Upcoming Scientific and Investor Conferences in June

TEL AVIV, Israel, May 30, 2017 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX), a specialty clinical stage pharmaceutical Company specializing in the development of cannabinoid-based drugs, today announced that the Company's management will present a company overview at three upcoming scientific and investor conferences in June:

The 7th Annual LD Micro Invitational:


Wednesday, June 7th, 2017Time:                    

2:30 PM PST Location:             

Luxe Sunset Boulevard Hotel, Los Angeles, CaliforniaPresenter:         

Josh Blacher, Chief Financial Officer

The 2017 Marcum MicroCap Conference:


Thursday, June 15th, 2017Time:                    

10:30 AM ESTLocation:             

Grand Hyatt New YorkPresenter:         

Josh Blacher, Chief Financial Officer

The 27th Annual ICRS Symposium on the Cannabinoids:


June 22nd – 27th, 2017Venue:                               

Poster PresentationLocation:             

Le Centre Sheraton, Montréal, CanadaPresenter:         

Dr. Elran Haber, Chief Executive Officer and Dr. Adi Zuloff-Shani, Chief Technology Officer

About Therapix Biosciences:Therapix Biosciences Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists, focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the company is currently engaged in two internal drug development programs based on repurposing an FDA approved synthetic cannabinoid (dronabinol): THX-TS01 targets to the treatment of Tourette's syndrome; and THX-ULD01 targets the high-value and under-served market of mild cognitive impairments. Please visit our website for more information at

For further information: Investor Contact: Josh Blacher, CFO, Therapix Biosciences,

To view the original version on PR Newswire, visit:

SOURCE Therapix Biosciences Ltd
Copyright©2017 PR Newswire.
All rights reserved

Related medicine technology :

1. Therapix Biosciences Ltd. Announces Full Exercise of Underwriters Over-Allotment Option
2. Therapix Biosciences Ltd. Announces Closing of U.S. Initial Public Offering of American Depositary Shares; 2,000,000 American Depository Shares Priced at $6.00 per ADS
3. Therapix Biosciences Ltd. Announces Pricing of U.S. Initial Public Offering and NASDAQ Listing
4. Therapix Biosciences Provides Portfolio Update
5. The Israeli Pharma Company Therapix, is Joined by Five Internationally Renowned Experts, From Israel and the World, in the Field of Psychiatry and Tourette
6. 3-V Biosciences to Present Data at the AACR 2017 Annual Meeting in Washington, DC
7. Avelas Biosciences to Present at Needham & Company 16th Annual Healthcare Conference
8. Pressure BioSciences, Inc. Discusses Research Market, Goals and Milestones for First Half of 2017 in New SNNLive Video Interview with
9. Neurocrine Biosciences Announces Conference Call and Webcast to Report Fourth Quarter and Year-End 2016 Results
10. How These Generic Drugs Stocks are Faring? -- Neurocrine Biosciences, Evoke Pharma, SCYNEXIS, and Eagle Pharma
11. Hope Biosciences Acquires Worldwide Rights To Novel MERTK/AXL Inhibitor From NeoPharm
Post Your Comments:
(Date:10/10/2017)... 10, 2017  NDS received FDA 510(k) clearance in May 2017 ... display stand specifically designed for endoscopy environments. An innovative secondary monitor ... clinical solution to support the improvement of patient outcomes, procedural efficiency, ... ... ...
(Date:10/7/2017)... --  Provista, a proven leader in the supply ... power, today announced a new resource area on ... is the online home for case studies, articles on ... releases, slideshows and events. ... at their fingertips, viewers can also watch short videos ...
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
Breaking Medicine Technology:
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... IsoComforter, Inc. ... products, announced today the introduction of an innovative new design of the shoulder pad. ... so you get maximum comfort while controlling your pain while using cold therapy. By ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... (HLA), the nation's first interactive health literacy software tool, and the Cancer Patient ... aspects of cancer patient education, today announce a new strategic alliance. , ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of California Berkeley, and other leading institutions in announcing the launch of the ... to change the way animals are raised for food. , Founding members of ...
Breaking Medicine News(10 mins):